# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cramer gives his take on E.l.f Beauty, Acadia Pharmaceuticals, B&G Foods, Lucid, SoFi, Dell, Johnson & Johnson, UWM and...
Citigroup analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $30...
UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $25 to ...
HC Wainwright & Co. analyst Andrew Fein reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintains $27 pri...
Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $30 to ...
Cantor Fitzgerald analyst Charles Duncan maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and lowers the pri...
RBC Capital analyst Gregory Renza maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price targ...